Article Text

Download PDFPDF
Recent advances in the epidemiology, diagnosis and treatment of endomyocardial fibrosis in Africa
  1. Ana Olga H Mocumbi1,
  2. Ayodele O Falase2
  1. 1Universidade Eduardo Mondlane and Instituto Nacional de Saúde, Maputo, Moçambique
  2. 2Department of Medicine, University College Hospital, Ibadan, Nigeria
  1. Correspondence to Professor Ana Olga H Mocumbi, Department of Medicine, Universidade Eduardo Mondlane & Instituto Nacional de Saúde, Av Eduardo Mondlane 1008, PO Box 264, Maputo Moçambique; amocumbi{at}


Endomyocardial fibrosis (EMF) continues to be an important and disabling disease in many parts of Africa, although its prevalence has declined in some parts of the continent. Increased access to medical care in general and increased availability of echocardiography in some parts of the continent have led to recognition of the disease in areas in which the disease had not been previously reported, and this has given new insights into its natural history. However, the early manifestations of EMF continue to elude clinicians and researchers, and no progress has been made in defining its aetiology. Advances have, however, been made in establishing the epidemiology and improving clinical diagnosis and management, through modern medical therapy and improved surgical techniques. Research is still required to define clinical, biological and echocardiographic markers of early stages of EMF, so that advances in the knowledge of its pathogenesis and pathophysiology can be made. This will hopefully determine preventive measures and avoid the burden of this debilitating condition in this continent.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles